Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

We came across a bullish thesis on Amgen Inc. (AMGN) on Substack by Magnus Ofstad. In this article, we will summarize the ...

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Amgen ...

Amgen (AMGN) stock in focus as its antibody drug Tepezza becomes U.K.'s first medicine for adults with moderate to severe ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

A long-term study shows no survival advantage for a second transplant in relapsed myeloma, challenging traditional treatment ...

Bayesian Capital Management made a big biotech play, grabbing 43,000 shares of Amgen worth over $11 million, making it their ...

Investors reacted negatively to the news. The company’s stock fell more than 16% yesterday. It’s also a setback in ...

Behind losses for shares of Merck and Amgen, the Dow Jones Industrial Average is falling Tuesday afternoon.

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and ...

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at ...

PDT Partners gave Amgen a big fourth-quarter vote of confidence, ramping up its stake by a whopping 480.6%. Institutional ...